Study to Determine the Response and Effectiveness of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter

Phase 3 Completed 276 enrolled Astellas Pharma Inc Advanz Pharma · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to demonstrate the effectiveness of RSD1235 compared with placebo, in the conversion of atrial fibrillation or atrial flutter to sinus rhythm.

Timeline

Start: 2004-06
Primary completion: 2005-06
Completion: 2005-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Vernakalant	Other / unclassified	—	—

Study to Determine the Response and Effectiveness of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter

Summary

Timeline

Drugs

Indications